Cargando…
Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy
Aims: Renal renin-angiotensin system (RAS) plays a pivotal role in the development of diabetic nephropathy (DN). Angiotensin II (Ang II) type 1 receptor (AT(1)R) blockade elevates (pro)renin, which may bind to (pro)renin receptor (PRR) and exert receptor-mediated, angiotensin-independent profibrotic...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635681/ https://www.ncbi.nlm.nih.gov/pubmed/29056916 http://dx.doi.org/10.3389/fphys.2017.00758 |
_version_ | 1783270337955233792 |
---|---|
author | Zhang, Lin An, Xiao-Fei Ruan, Xin Huang, Dong-Dong Zhou, Li Xue, Hong Lu, Li-Min He, Ming |
author_facet | Zhang, Lin An, Xiao-Fei Ruan, Xin Huang, Dong-Dong Zhou, Li Xue, Hong Lu, Li-Min He, Ming |
author_sort | Zhang, Lin |
collection | PubMed |
description | Aims: Renal renin-angiotensin system (RAS) plays a pivotal role in the development of diabetic nephropathy (DN). Angiotensin II (Ang II) type 1 receptor (AT(1)R) blockade elevates (pro)renin, which may bind to (pro)renin receptor (PRR) and exert receptor-mediated, angiotensin-independent profibrotic effects. We therefore investigated whether PRR activation leads to the limited anti-fibrotic effects of AT(1)R blockade on DN, and whether PRR inhibition might ameliorate progression of DN. Methods: To address the issue, the expression of RAS components was tested in different stages of streptozotocin (STZ)-induced diabetic rats (6, 12, and 24 weeks) and 6-week AT(1)R blockade (losartan) treated diabetic rats. Using the blocker for PRR, the handle region peptide (HRP) of prorenin, the effects of PRR on high glucose or Ang II-induced proliferative and profibrotic actions were evaluated by measurement of cell proliferation, matrix metalloproteinase-2 (MMP-2) activity, activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and transforming growth factor-β1 (TGF-β1) expression in rat mesangial cells (MCs). Results: PRR was downregulated in the kidneys of different stages of diabetic rats (6, 12, and 24 weeks). Moreover, 6-week losartan treatment further suppressed PRR expression via upregulating AT(2)R, and ameliorated diabetic renal injury. HRP inhibited high glucose and Ang II-induced proliferative and profibrotic effects in MCs through suppressing TGF-β1 expression and activating MMP-2. Meanwhile, HRP enhanced losartan's anti-fibrotic effects through further inhibiting phosphorylation of ERK1/2 and TGF-β1 expression. Moreover, the inhibitive effect of HRP on Ang II-induced TGF-β1 expression depended on the regulation of PRR expression by AT(2)R. Conclusions: Our findings suggest that inhibition of PRR contributes to renoprotection against diabetic nephropathy by AT(1)R blockade. |
format | Online Article Text |
id | pubmed-5635681 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-56356812017-10-20 Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy Zhang, Lin An, Xiao-Fei Ruan, Xin Huang, Dong-Dong Zhou, Li Xue, Hong Lu, Li-Min He, Ming Front Physiol Physiology Aims: Renal renin-angiotensin system (RAS) plays a pivotal role in the development of diabetic nephropathy (DN). Angiotensin II (Ang II) type 1 receptor (AT(1)R) blockade elevates (pro)renin, which may bind to (pro)renin receptor (PRR) and exert receptor-mediated, angiotensin-independent profibrotic effects. We therefore investigated whether PRR activation leads to the limited anti-fibrotic effects of AT(1)R blockade on DN, and whether PRR inhibition might ameliorate progression of DN. Methods: To address the issue, the expression of RAS components was tested in different stages of streptozotocin (STZ)-induced diabetic rats (6, 12, and 24 weeks) and 6-week AT(1)R blockade (losartan) treated diabetic rats. Using the blocker for PRR, the handle region peptide (HRP) of prorenin, the effects of PRR on high glucose or Ang II-induced proliferative and profibrotic actions were evaluated by measurement of cell proliferation, matrix metalloproteinase-2 (MMP-2) activity, activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and transforming growth factor-β1 (TGF-β1) expression in rat mesangial cells (MCs). Results: PRR was downregulated in the kidneys of different stages of diabetic rats (6, 12, and 24 weeks). Moreover, 6-week losartan treatment further suppressed PRR expression via upregulating AT(2)R, and ameliorated diabetic renal injury. HRP inhibited high glucose and Ang II-induced proliferative and profibrotic effects in MCs through suppressing TGF-β1 expression and activating MMP-2. Meanwhile, HRP enhanced losartan's anti-fibrotic effects through further inhibiting phosphorylation of ERK1/2 and TGF-β1 expression. Moreover, the inhibitive effect of HRP on Ang II-induced TGF-β1 expression depended on the regulation of PRR expression by AT(2)R. Conclusions: Our findings suggest that inhibition of PRR contributes to renoprotection against diabetic nephropathy by AT(1)R blockade. Frontiers Media S.A. 2017-10-06 /pmc/articles/PMC5635681/ /pubmed/29056916 http://dx.doi.org/10.3389/fphys.2017.00758 Text en Copyright © 2017 Zhang, An, Ruan, Huang, Zhou, Xue, Lu and He. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Physiology Zhang, Lin An, Xiao-Fei Ruan, Xin Huang, Dong-Dong Zhou, Li Xue, Hong Lu, Li-Min He, Ming Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy |
title | Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy |
title_full | Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy |
title_fullStr | Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy |
title_full_unstemmed | Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy |
title_short | Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy |
title_sort | inhibition of (pro)renin receptor contributes to renoprotective effects of angiotensin ii type 1 receptor blockade in diabetic nephropathy |
topic | Physiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635681/ https://www.ncbi.nlm.nih.gov/pubmed/29056916 http://dx.doi.org/10.3389/fphys.2017.00758 |
work_keys_str_mv | AT zhanglin inhibitionofproreninreceptorcontributestorenoprotectiveeffectsofangiotensiniitype1receptorblockadeindiabeticnephropathy AT anxiaofei inhibitionofproreninreceptorcontributestorenoprotectiveeffectsofangiotensiniitype1receptorblockadeindiabeticnephropathy AT ruanxin inhibitionofproreninreceptorcontributestorenoprotectiveeffectsofangiotensiniitype1receptorblockadeindiabeticnephropathy AT huangdongdong inhibitionofproreninreceptorcontributestorenoprotectiveeffectsofangiotensiniitype1receptorblockadeindiabeticnephropathy AT zhouli inhibitionofproreninreceptorcontributestorenoprotectiveeffectsofangiotensiniitype1receptorblockadeindiabeticnephropathy AT xuehong inhibitionofproreninreceptorcontributestorenoprotectiveeffectsofangiotensiniitype1receptorblockadeindiabeticnephropathy AT lulimin inhibitionofproreninreceptorcontributestorenoprotectiveeffectsofangiotensiniitype1receptorblockadeindiabeticnephropathy AT heming inhibitionofproreninreceptorcontributestorenoprotectiveeffectsofangiotensiniitype1receptorblockadeindiabeticnephropathy |